Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...
Hosted on MSN4h
Goldman Sachs Downgrades Moderna (MRNA)Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
A freshman Idaho lawmaker wants to ban most COVID-19 shots for the next decade, with a bill rooted in misconceptions about ...
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Meet the woman leading vaccine innovation in Senegal to fight Rift Valley fever and empower Africa’s next generation of ...
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $44.94 which represents a slight increase of $3.29 or 7.90% from the prior close of $41.65. The stock opened at $41.99 and touched a low ...
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback